Finasteride vs dutasteride for hair loss: which 5-alpha reductase inhibitor fits Malaysians better?
How finasteride and dutasteride differ on enzyme targets, doses, trial evidence, sexual and mood risks, blood donation and 2025 regulator warnings, written for Malaysians choosing with a doctor.
When Malaysians compare oral options for pattern hair loss, two names dominate the conversation: finasteride and dutasteride. Both are 5-alpha reductase inhibitors. Both lower dihydrotestosterone (DHT). Both need a doctor's prescription in Malaysia. They are not interchangeable tablets, and the choice is not only about which one "works more".
This guide explains how the hair cycle and DHT connect to these drugs, how type I and type II 5-alpha reductase differ, what typical doses look like, what head-to-head and network evidence shows, how side-effect and safety labelling evolved in 2025, what timelines to expect, and a practical checklist before you decide with a doctor. It is general information, not personal medical advice. For single-drug deep dives, see finasteride for hair loss and dutasteride for hair loss. Related reading includes finasteride side effects, minoxidil and finasteride together, topical finasteride, is finasteride worth it, DHT and hair loss, and male pattern baldness treatment.
The short answer
- Same pathway, different enzyme coverage. Finasteride mainly blocks type II 5-alpha reductase. Dutasteride blocks type I and type II. Both reduce conversion of testosterone to DHT, which drives miniaturisation in androgenetic alopecia 1 2.
- Doses people discuss. Finasteride 1 mg daily is the classic oral dose studied for male pattern hair loss. Dutasteride 0.5 mg daily is the dose used in many hair-loss trials and in long-term Asian chart reviews; in many countries that dose is labelled for enlarged prostate and used off-label for hair loss unless a local hair-loss label exists 3 4 5.
- Efficacy signal favours dutasteride in several analyses. A 2019 meta-analysis of randomised trials found greater hair-count and photographic gains with dutasteride than with finasteride over about 24 weeks, with similar reported rates of sexual side effects in those trials 3. A 2022 network meta-analysis ranked oral dutasteride 0.5 mg among the strongest medical options for total hair growth at 24 weeks in men 6.
- Neither tablet is risk-free. Sexual side effects, mood changes, and fertility planning all need an honest discussion. In May 2025 the European Medicines Agency confirmed suicidal thoughts as a side effect of finasteride tablets and added precautionary mood-change information for dutasteride; Malaysia's NPRA/MADRAC 2025 bulletin reflects the same class of safety messaging for both drugs 7 8.
- Dutasteride stays in the body much longer. Its long half-life (on the order of weeks) means blood-donation rules and pregnancy precautions matter for months after the last dose 5.
- No tablet is a complete answer alone. Guidelines still treat evidence-based medical therapy (often including topical minoxidil) as the foundation, with oral 5-alpha reductase inhibitors as a mainstay for many men 9 10. See minoxidil in Malaysia.
Hair cycle, DHT and the two enzyme types
The hair cycle in plain language
Every scalp follicle cycles through a long growing phase (anagen), a short transition (catagen), and a resting phase (telogen), after which the old hair sheds and a new cycle can begin. On a healthy scalp, anagen lasts years, which is why scalp hair can grow long 2.
Miniaturisation
In androgenetic alopecia, genetically sensitive follicles on the top of the head respond to androgens. An enzyme family called 5-alpha reductase converts testosterone into DHT. DHT binds androgen receptors in follicle cells. Over many cycles the growing phase shortens and the follicle shrinks, so thick pigmented hairs are gradually replaced by thin, short, pale ones 1 2. In men this often shows as a receding hairline and thinning crown. Women can have pattern thinning too, but oral finasteride and dutasteride are generally discussed for men, not as routine self-started options for women of childbearing potential.
Type I versus type II 5-alpha reductase
There is more than one form of the enzyme:
- Type II is abundant in scalp hair follicles and prostate tissue. Finasteride is relatively selective for type II.
- Type I is found in skin (including scalp skin) and other tissues. Dutasteride inhibits both type I and type II.
That dual blockade is why dutasteride suppresses serum DHT more strongly in laboratory and clinical pharmacology work than finasteride does. Stronger DHT suppression is not automatically "better for every person". It is one reason doctors weigh potency against half-life, labelling, and individual risk 1 3.
How finasteride works
Finasteride occupies type II 5-alpha reductase and lowers DHT production. For male pattern hair loss, the widely studied oral dose is 1 mg once daily. Large randomised programmes and long-term extensions showed that many men preserve hair or improve photographic appearance while they keep taking it, and that gains tend to fade if the drug is stopped 11 12 9.
Finasteride does not create new follicles from nothing. It can help existing miniaturising follicles produce thicker shafts for longer cycles in men who respond. Response varies. Frontal hairlines are often harder than the crown. See finasteride and side effects.
How dutasteride works
Dutasteride inhibits type I and type II 5-alpha reductase. The 0.5 mg capsule is familiar from prostate treatment. Hair-loss doctors may prescribe the same strength when they judge that a dual inhibitor is appropriate. Randomised comparisons and meta-analyses suggest, on average, larger hair-count gains than with finasteride over mid-term follow-up 3 6.
Because dutasteride is not labelled for hair loss in every country the same way finasteride 1 mg is, prescribing is often framed as off-label use for androgenetic alopecia. That does not mean the trials are imaginary. It does mean the conversation with a Malaysian doctor should cover indication, monitoring, and what "off-label" means in practice 5 13. See dutasteride.
Head-to-head and network evidence (without overselling the averages)
Zhou et al. meta-analysis (2019)
Zhou and colleagues pooled three randomised trials (576 men) comparing dutasteride with finasteride over a 24-week window. Dutasteride showed a larger mean change in total hair count (mean difference about 28.6 hairs in the pooled analysis), better investigator and panel photographic scores for vertex and frontal views, and better subject assessment scores. Rates of altered libido, erectile dysfunction, and ejaculation disorders did not differ significantly between the two drugs in that pooled safety look 3.
Network meta-analysis (JAMA Dermatology, 2022)
A network meta-analysis compared relative efficacy of minoxidil regimens and 5-alpha reductase inhibitors for male androgenetic alopecia. At 24 weeks, oral dutasteride 0.5 mg ranked among the most efficacious options for total hair growth in that model, ahead of several finasteride and minoxidil arms on the outcomes studied 6. Network rankings are model-based. They help with relative ordering. They do not replace an individual doctor's assessment of contraindications and preference.
Korean multicentre chart review (long-term)
A South Korean multicentre retrospective chart review followed hundreds of men treated with dutasteride or finasteride for years in routine care. Among patients on recommended doses, improvement rates were substantially higher with dutasteride than with finasteride for basic-type and M-pattern loss over roughly three years, while overall adverse-event rates were in a similar low double-digit or high single-digit range depending on the group 4. Chart reviews are not randomised. They still matter because hair-loss drugs are taken for years, and short trials alone cannot show that.
What this means in one sentence
Across different study designs, dutasteride often looks more potent on hair-count and photographic outcomes, while sexual adverse-event rates in controlled comparisons look broadly similar. Potency is not the only decision factor for a Malaysian patient.
Comparison table
| Point | Finasteride | Dutasteride |
|---|---|---|
| Main enzyme target | Type II 5-alpha reductase | Type I and type II |
| Common oral dose discussed for AGA | 1 mg daily | 0.5 mg daily (often off-label for AGA) |
| Relative efficacy signal in meta-analyses | Strong evidence base; usually less hair-count gain than dutasteride in head-to-head pools 3 11 | Often larger mid-term hair-count/photo gains 3 6 4 |
| Half-life (order of magnitude) | Hours | Weeks (long tissue persistence) 5 |
| Blood donation | Ask the blood service and your doctor | Typically avoided while taking and for months after stopping 5 |
| Sexual side effects | Documented; discuss early 14 | Documented at similar rates in several comparisons 3 14 |
| 2025 mood / suicidal-thoughts labelling | Suicidal ideation confirmed as a side effect of tablets by EMA; stop and seek help if mood changes on 1 mg for hair loss 7 | Precautionary class information on mood changes added; seek help if mood changes 7 8 |
| Malaysian access | Prescription-only medicine; confirm registered product with a pharmacist or NPRA resources 13 | Prescription-only; confirm indication and product with the prescribing doctor 13 |
Pros, cons and risks
Finasteride: practical pros
- Decades of male AGA trial data and guideline familiarity 9 11.
- Shorter half-life than dutasteride, which some clinicians and patients prefer when planning fertility or a trial stop.
- Clear 1 mg AGA dosing tradition in many markets 15 16.
Finasteride: practical cons and risks
- Sexual dysfunction (lower desire, erectile difficulty, ejaculation changes) occurs in a minority; rates vary by study design 14.
- Mood changes, including depression and suicidal thoughts, are now explicitly highlighted in major regulator communications for tablets 7 8.
- Must not be used by women who are or may become pregnant; crushed or broken tablets raise handling concerns 17.
- Stopping usually leads to gradual return toward the pre-treatment trajectory over months 11.
Dutasteride: practical pros
- Dual enzyme blockade and stronger average DHT suppression.
- Favourable head-to-head and network efficacy signals versus finasteride for many hair outcomes 3 6.
- Long-term Asian real-world chart data supporting sustained use under medical care 4.
Dutasteride: practical cons and risks
- Long half-life complicates washout, blood donation, and pregnancy-exposure planning 5.
- Often off-label for AGA depending on local labelling, so documentation and consent matter 13.
- Sexual and mood-related risks still need the same careful counselling as finasteride 14 7.
- Lowers PSA; tell any doctor ordering a prostate blood test 5.
Sexual side effects, fertility and blood donation
A systematic review and meta-analysis of sexual adverse effects with finasteride or dutasteride for male AGA found that these events are real for some men, even when absolute rates are modest in randomised settings 14. Online forums amplify rare and severe stories; trial tables can under-capture lived experience. A balanced Malaysian conversation covers:
- baseline sexual function before starting;
- what to do if function changes (contact the doctor promptly; do not silently double the dose);
- whether a planned pregnancy with a partner means delaying, choosing another option, or planning a washout with medical advice;
- blood donation: dutasteride users are typically told not to donate while taking the drug and for a long period after stopping so that a pregnant recipient never receives it 5;
- that "post-finasteride" symptom clusters are discussed in the literature and remain scientifically contested in scope, so neither dismissive nor catastrophic framing helps 18.
Timelines: 3, 6 and 12 months
Hair cycles are slow. Judging an oral 5-alpha reductase inhibitor after two weeks is not useful.
- Around 3 months: shedding patterns may still fluctuate. Some men notice early texture or density changes; many do not yet see a clear photographic win. Side-effect screening matters more than victory photos at this stage 9.
- Around 6 months: a fairer first efficacy checkpoint for density and vertex photos, ideally with consistent lighting and a doctor review 3 12.
- Around 12 months: a better window for deciding whether to continue, switch under supervision, or add other evidence-based steps such as topical minoxidil if not already used 10 9.
If the drug is stopped, expect months of drift back toward the genetic pattern rather than an overnight crash, though individual courses vary 11.
Malaysian context: prescription rules and 2025 safety communications
In Malaysia, finasteride and dutasteride are not casual pharmacy impulse buys for hair loss. They are prescription medicines. Confirm the product, strength, and counselling with a registered doctor and pharmacist, and use NPRA resources when you need to check what is officially registered 13.
In May 2025, EMA's safety committee confirmed suicidal ideation as a side effect of finasteride tablets (frequency unknown), noted that most such reports involved people using 1 mg for hair loss, and advised patients on 1 mg who develop mood changes to stop and seek medical advice. Sexual dysfunction can contribute to mood changes and should also prompt medical contact. A patient card was planned for 1 mg packs in the EU. For dutasteride, reviewers could not establish a direct link to suicidal ideation from the data reviewed, but because the drugs share a mechanism, mood-change information was added as a precaution. Benefits were still judged to outweigh risks for approved uses 7.
Malaysia's NPRA/MADRAC Bulletin Vol. 56 Issue 05-2025 carries related safety communication for healthcare professionals and the public on this class of issues for finasteride and dutasteride 8. Treat mood or suicidal thoughts as urgent medical issues, not as something to "push through" for hair.
Hair centres in Malaysia can help with scalp assessment and non-drug options, but oral 5-alpha reductase inhibitors still belong under a prescribing doctor's care. Do not import unmarked tablets from social media sellers.
Myths worth retiring
- "Dutasteride always works and finasteride never does." False. Averages favour dutasteride in several analyses, but many men do well on finasteride, and some do poorly on either 3 11.
- "If sexual side effects have not appeared by month one, they never will." Unreliable. Report changes whenever they appear 14.
- "More milligrams must be better." Self-escalating doses without a doctor raises risk without a proven personal benefit.
- "One short course ends pattern baldness." False. These drugs do not end pattern hair loss. They can slow further thinning and improve density in responders while taken 9.
- "Topical versions remove all systemic risk." Topical finasteride still needs caution; regulators have warned about compounded products and systemic exposure is possible 19. See topical finasteride.
- "Women can share a partner's tablets." No. Pregnancy exposure is a hard stop for handling and use 17 5.
Practical checklist before you choose
- Confirm the diagnosis is pattern hair loss (or another condition that truly warrants these drugs), not only stress shedding or scalp inflammation 2.
- Review medicines, liver history, mood history, and sexual-function baseline with a doctor.
- Ask whether finasteride 1 mg, dutasteride 0.5 mg, topical minoxidil, or a combination fits your stage and risk tolerance 9 6. See using both minoxidil and finasteride.
- Clarify labelling: on-label AGA versus off-label AGA for dutasteride in your case 13.
- Agree a review date at about 3 and 6 months, with photos.
- Know the red flags: mood change, suicidal thoughts, painful breasts, severe sexual dysfunction, allergic reaction. Stop and seek care as advised for your drug 7 8.
- Plan fertility, contraception for partners, and blood-donation status before the first box is opened 5 17.
- Avoid buying unmarked "hair loss DHT blockers" online without a prescription trail.
Where this leaves a Malaysian reader
If you want the option with the larger mid-term efficacy signal in pooled and network analyses, dutasteride often ranks higher, at the cost of a longer half-life and frequent off-label framing for AGA 3 6 4. If you want the most familiar AGA oral evidence base and a shorter pharmacokinetic tail, finasteride 1 mg remains a guideline-backed mainstay 9 11. Either way, 2025 regulator messaging means mood and sexual symptoms need a low threshold for contact with a doctor 7 8. Pairing an oral choice with topical minoxidil is common in practice when the doctor agrees 10. Experimental anti-androgens and degraders such as GT20029 are not substitutes for today's prescription decisions.
The useful question is not "which drug is famous on forums". It is "which supervised plan matches my pattern, my risks, and my willingness to continue for years".
Frequently asked questions
Is dutasteride always stronger than finasteride for hair?
On average, several randomised comparisons and a network meta-analysis find larger hair-count or growth signals with dutasteride 0.5 mg than with finasteride at usual hair-loss doses 3 6. Averages are not promises for one person. Finasteride still helps many men and has a long AGA evidence trail 11 9.
Can I start either drug without a prescription in Malaysia?
No. Treat both as prescription medicines. Confirm the product through a registered doctor and pharmacist, and use NPRA resources when you need registration checks 13. Unmarked online tablets are a safety risk.
How long before I judge the result?
Plan reviews around 3 months for safety and early change, about 6 months for a fairer efficacy look, and about 12 months for a fuller decision on continuing or adjusting 9 3. Hair cycles are slow.
What sexual side effects should I watch for?
Lower desire, erectile difficulty, and ejaculation changes are the ones most often discussed. They affect a minority in trials, but they matter when they happen. Contact your doctor rather than silently stopping or doubling doses 14 3.
Why do regulators talk about mood and suicidal thoughts in 2025?
EMA confirmed suicidal thoughts as a side effect of finasteride tablets and added precautionary mood information for dutasteride. Malaysia's NPRA/MADRAC 2025 bulletin communicates related class safety messages. If mood drops or suicidal thoughts appear on 1 mg finasteride for hair loss, stop and seek medical help promptly 7 8.
Why is blood donation a big deal with dutasteride?
Dutasteride persists for a long time. Blood services typically advise against donation while taking it and for months after stopping, to protect a pregnant recipient 5. Ask your doctor and the blood service for the exact local rule.
Should women take these tablets for thinning hair?
Oral finasteride and dutasteride are generally for men in this context. Women who are or may become pregnant must not take them or handle leaking or crushed product 17 5. Women with pattern thinning need a separate medical plan.
Do I still need minoxidil if I take finasteride or dutasteride?
Many evidence-based plans combine a DHT-pathway drug with topical minoxidil because they work through different mechanisms 10 9. Whether that mix suits you is a doctor decision. See minoxidil and finasteride together and minoxidil in Malaysia.
Sources
- PubMed. Androgenetic alopecia: a review, Endocrine, 2017. accessed 27 Oct 2026
- DermNet. Male pattern hair loss. accessed 27 Oct 2026
- PubMed. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis, Clin Interv Aging, 2019. accessed 27 Oct 2026
- Annals of Dermatology / PMC. Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study (Choi et al.), accessed 7 Nov 2026. accessed 27 Oct 2026
- MedlinePlus (US National Library of Medicine). Dutasteride. accessed 27 Oct 2026
- PubMed. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis, JAMA Dermatology, 2022. accessed 27 Oct 2026
- European Medicines Agency (EMA). Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines (PRAC review, 8 May 2025), 8 May 2025. accessed 27 Oct 2026
- National Pharmaceutical Regulatory Agency (NPRA) / MADRAC, Malaysia. MADRAC Bulletin Vol. 56 Issue 05-2025 (safety communication covering finasteride and dutasteride mood and suicidal-thoughts labelling updates), 2025. accessed 27 Oct 2026
- PubMed. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version, J Eur Acad Dermatol Venereol, 2018. accessed 27 Oct 2026
- PubMed. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis, J Am Acad Dermatol, 2017. accessed 27 Oct 2026
- PubMed. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia, Eur J Dermatol, 2002. accessed 27 Oct 2026
- PubMed. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo, J Am Acad Dermatol, 2012. accessed 27 Oct 2026
- National Pharmaceutical Regulatory Agency (NPRA), Malaysia. NPRA official website: product registration and QUEST product search, accessed 31 Oct 2026. accessed 27 Oct 2026
- PubMed. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis, Acta Derm Venereol, 2019. accessed 27 Oct 2026
- NHS. Finasteride. accessed 27 Oct 2026
- DermNet. Finasteride. accessed 27 Oct 2026
- NHS. Fertility and pregnancy while taking finasteride. accessed 27 Oct 2026
- PubMed. Post-finasteride syndrome, An Bras Dermatol, 2020. accessed 27 Oct 2026
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products (22 Apr 2025). accessed 27 Oct 2026
Educational content. Not medical advice.